MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression

Cancer Letters

Volumn 347, Issue 1, 2014, Pages 54-64

  Patel, Kripa ^a   Kollory, Anita ^a   Takashima, Asami ^a   Sarkar, Sibaji ^a   Faller, Douglas V ^a   Ghosh, Sajal K ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EMT; Let 7; Pancreatic cancer; SOCS3; STAT3

Indexed keywords

INTERLEUKIN 6; JANUS KINASE 2; MICRORNA; MICRORNA LET 7; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EMT; LET-7; PANCREATIC CANCER; SOCS3; STAT3;

BASE SEQUENCE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; HUMANS; MICRORNAS; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84897082706     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.020     Document Type: Article

References (68)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60:277-300.
2. Kleeff J., Michalski C.W., Friess H., Buchler M.W. Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies. Eur. J. Surg. Oncol. 2007, 33:817-823.
3. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
4. Poplin E., Feng Y., Berlin J., Rothenberg M.L., Hochster H., Mitchell E., Alberts S., O'Dwyer P., Haller D., Catalano P., Cella D., Benson A.B. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2009, 27:3778-3785.
5. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., Neuhaus H., Haag C., Clemens M., Heinrich B., Vehling-Kaiser U., Fuchs M., Fleckenstein D., Gesierich W., Uthgenannt D., Einsele H., Holstege A., Hinke A., Schalhorn A., Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2006, 24:3946-3952.
6. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., Bennouna J., Bachet J.B., Khemissa-Akouz F., Pere-Verge D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825.
7. Schneider G., Schmid R.M. Genetic alterations in pancreatic carcinoma. Mol. Cancer 2003, 2:15.
8. Hezel A.F., Kimmelman A.C., Stanger B.Z., Bardeesy N., Depinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006, 20:1218-1249.
9. Chiu J., Yau T. Metastatic pancreatic cancer: are we making progress in treatment?. Gastroenterol. Res. Pract. 2012, 2012:898931.
10. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
11. Perez-Mancera P.A., Guerra C., Barbacid M., Tuveson D.A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012, 142:1079-1092.
12. Scholz A., Heinze S., Detjen K.M., Peters M., Welzel M., Hauff P., Schirner M., Wiedenmann B., Rosewicz S. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003, 125:891-905.
13. Toyonaga T., Nakano K., Nagano M., Zhao G., Yamaguchi K., Kuroki S., Eguchi T., Chijiiwa K., Tsuneyoshi M., Tanaka M. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett. 2003, 201:107-116.
14. Ihle J.N. STATs: signal transducers and activators of transcription. Cell 1996, 84:331-334.
15. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
16. Cao X., Tay A., Guy G.R., Tan Y.H. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 1996, 16:1595-1603.
17. Abdulghani J., Gu L., Dagvadorj A., Lutz J., Leiby B., Bonuccelli G., Lisanti M.P., Zellweger T., Alanen K., Mirtti T., Visakorpi T., Bubendorf L., Nevalainen M.T. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 2008, 172:1717-1728.
18. Berishaj M., Gao S.P., Ahmed S., Leslie K., Al-Ahmadie H., Gerald W.L., Bornmann W., Bromberg J.F. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007, 9:R32.
19. Bharti A.C., Donato N., Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 2003, 171:3863-3871.
20. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
21. Gao H., Ward P.A. STAT3 and suppressor of cytokine signaling 3: potential targets in lung inflammatory responses. Expert Opin. Ther. Targets 2007, 11:869-880.
22. Glienke W., Hausmann E., Bergmann L. Targeting STAT3 signaling in pancreatic cancer promotes antiapoptotic gene expression. Pancreas 2011, 40:323-324.
23. Nagaraj N.S., Washington M.K., Merchant N.B. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin. Cancer Res. 2011, 17:483-493.
24. McCleary-Wheeler A.L., Lomberk G.A., Weiss F.U., Schneider G., Fabbri M., Poshusta T.L., Dusetti N.J., Baumgart S., Iovanna J.L., Ellenrieder V., Urrutia R., Fernandez-Zapico M.E. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 2013, 328:212-221.
25. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
26. Szafranska A.E., Davison T.S., John J., Cannon T., Sipos B., Maghnouj A., Labourier E., Hahn S.A. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26:4442-4452.
27. Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 2007, 120:1046-1054.
28. Ali S., Almhanna K., Chen W., Philip P.A., Sarkar F.H. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am. J. Transl. Res. 2011, 3:28-47.
29. Torrisani J., Bournet B., du Rieu M.C., Bouisson M., Souque A., Escourrou J., Buscail L., Cordelier P. Let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum. Gene. Ther. 2009, 20:831-844.
30. Ali S., Saleh H., Sethi S., Sarkar F.H., Philip P.A. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br. J. Cancer 2012, 107:1354-1360.
31. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., Horvitz H.R., Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901-906.
32. Pasquinelli A.E., Reinhart B.J., Slack F., Martindale M.Q., Kuroda M.I., Maller B., Hayward D.C., Ball E.E., Degnan B., Muller P., Spring J., Srinivasan A., Fishman M., Finnerty J., Corbo J., Levine M., Leahy P., Davidson E., Ruvkun G. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000, 408:86-89.
33. Boyerinas B., Park S.M., Hau A., Murmann A.E., Peter M.E. The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 2010, 17:F19-F36.
34. Hertel J., Bartschat S., Wintsche A., Otto C., Stadler P.F. Evolution of the let-7 microRNA family. RNA Biol. 2012, 9:231-241.
35. Wang Y., Hu X., Greshock J., Shen L., Yang X., Shao Z., Liang S., Tanyi J.L., Sood A.K., Zhang L. Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS ONE 2012, 7:e44399.
36. Thornton J.E., Gregory R.I. How does Lin28 let-7 control development and disease?. Trends Cell Biol. 2012, 22:474-482.
37. Thomson J.M., Parker J., Perou C.M., Hammond S.M. A custom microarray platform for analysis of microRNA gene expression. Nat. Methods 2004, 1:47-53.
38. Bussing I., Slack F.J., Grosshans H. Let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med. 2008, 14:400-409.
39. Akao Y., Nakagawa Y., Naoe T. Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull. 2006, 29:903-906.
40. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T., Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-3756.
41. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., Song E. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
42. Ghosh S.K., Perrine S.P., Williams R.M., Faller D.V. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012, 119:1008-1017.
43. Corcoran R.B., Contino G., Deshpande V., Tzatsos A., Conrad C., Benes C.H., Levy D.E., Settleman J., Engelman J.A., Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011, 71:5020-5029.
44. Wulczyn F.G., Smirnova L., Rybak A., Brandt C., Kwidzinski E., Ninnemann O., Strehle M., Seiler A., Schumacher S., Nitsch R. Post-transcriptional regulation of the let-7 microRNA during neural cell specification. FASEB J. 2007, 21:415-426.
45. Sempere L.F., Freemantle S., Pitha-Rowe I., Moss E., Dmitrovsky E., Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004, 5:R13.
46. Schulman B.R., Esquela-Kerscher A., Slack F.J. Reciprocal expression of lin-41 and the microRNAs let-7 and mir-125 during mouse embryogenesis. Dev. Dyn. 2005, 234:1046-1054.
47. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell. Biol. 2006, 172:973-981.
48. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
49. Hotz B., Arndt M., Dullat S., Bhargava S., Buhr H.J., Hotz H.G. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin. Cancer Res. 2007, 13:4769-4776.
50. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
51. Watanabe M., Sheriff S., Lewis K.B., Tinch S.L., Cho J., Balasubramaniam A., Kennedy M.A. HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines. Cancer Lett. 2012, 315:18-27.
52. Rahman M.M., Qian Z.R., Wang E.L., Sultana R., Kudo E., Nakasono M., Hayashi T., Kakiuchi S., Sano T. Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br. J. Cancer 2009, 100:501-510.
53. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
54. Li L., Shaw P.E. Elevated activity of STAT3C due to higher DNA binding affinity of phosphotyrosine dimer rather than covalent dimer formation. J. Biol. Chem. 2006, 281:33172-33181.
55. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
56. Wang Y., Lu Y., Toh S.T., Sung W.K., Tan P., Chow P., Chung A.Y., Jooi L.L., Lee C.G. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J. Hepatol. 2010, 53:57-66.
57. Yagil Z., Nechushtan H., Kay G., Yang C.M., Kemeny D.M., Razin E. The enigma of the role of protein inhibitor of activated STAT3 (PIAS3) in the immune response. Trends Immunol. 2010, 31:199-204.
58. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., Alexander W.S. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 2003, 4:540-545.
59. Gough D.J., Corlett A., Schlessinger K., Wegrzyn J., Larner A.C., Levy D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.
60. Sugimura K., Miyata H., Tanaka K., Hamano R., Takahashi T., Kurokawa Y., Yamasaki M., Nakajima K., Takiguchi S., Mori M., Doki Y. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin. Cancer Res. 2012, 18:5144-5153.
61. Babon J.J., Nicola N.A. The biology and mechanism of action of suppressor of cytokine signaling 3. Growth Factors 2012, 30:207-219.
62. Silver J.S., Hunter C.A. Gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 2010, 88:1145-1156.
63. Wei T., Orfanidis K., Xu N., Janson P., Stahle M., Pivarcsi A., Sonkoly E. The expression of microRNA-203 during human skin morphogenesis. Exp. Dermatol. 2010, 19:854-856.
64. Lena A.M., Shalom-Feuerstein R., Rivetti Val Cervo P., Aberdam D., Knight R.A., Melino G., Candi E. miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ. 2008, 15:1187-1195.
65. Tiwari N., Gheldof A., Tatari M., Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin. Cancer Biol. 2012, 22:194-207.
66. Karamitopoulou E. Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link?. Front. Oncol. 2013, 3:221.
67. Yamada S., Fuchs B.C., Fujii T., Shimoyama Y., Sugimoto H., Nomoto S., Takeda S., Tanabe K.K., Kodera Y., Nakao A. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery 2013, 154:946-954.
68. Qiu T., Zhou L., Zhu W., Wang T., Wang J., Shu Y., Liu P. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol. 2013, 9:255-269.